If it passes in Congress, the unfortunately named Hatch-Waxman Integrity Act of 2018 would ultimately delay generic drug competition and increase drug prices.
California Health Care Foundation (CHCF) interviews Waxman Strategies Chairman Henry Waxman on the changing political landscape of health care reform.
Former Congressman Henry Waxman (D-Calif.) and chairman of Waxman Strategies participated last weekend in the Aspen Institute’s annual Spotlight Health event to talk about rising prescription drug prices, as well as, reminisce on the Affordable Care Act (ACA).
Prescription drug prices have reached an all-time high. FDA Commissioner Gottlieb has taken on the issue indirectly, and announced several actions by the FDA intended to increase generic drug competition and transparency.
Democrats shouldn’t impose litmus tests on health care.
Tyson Foods has announced a commitment to reduce greenhouse gas emissions and agricultural runoff pollution from grains grown for animal feed on two million acres of grain by 2020.
Today, the Commonwealth Fund published a blog post on the Bipartisan Budget Act of 2018, which will have an impact on Medicaid drug prices.
The Trump administration laid out a package of proposals to lower drug costs in the president’s budget for fiscal year 2019.
The CREATES Act tackles one of the numerous problems driving high drug prices that Waxman Strategies described in their recent report.